The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Anti–amyloid β autoantibodies in cerebral amyloid angiopathy–related inflammation: Implications for amyloid‐modifying therapies
Abstract
Objective: Cerebral amyloid angiopathy–related inflammation (CAA‐ri) is characterized by vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects with the recently defined amyloid‐related imaging abnormalities (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies. Herein, we investigated the role of anti–amyloid β (Aβ) autoantibodies in the acute and remission phases of CAA‐ri. Methods: We used a novel ultrasensitive technique on patients from a retrospective multicenter case–control study, and evaluated the anti‐Aβ autoantibody concentration in the cerebrospinal fluid (CSF) of 10 CAA‐ri, 8 CAA, 14 multiple sclerosis, and 25 control subjects. Levels of soluble Aβ40, Aβ42, tau, P‐181 tau, and APOE genotype were also investigated. Results: During the acute phase of CAA‐ri, anti‐Aβ autoantibodies were specifically increased and directly correlated with Aβ mobilization, together with augmented tau and P‐181 tau. Following clinical and radiological remission, autoantibodies progressively returned to control levels, and both soluble Aβ and axonal degeneration markers decreased in parallel. Interpretation: Our data support the hypothesis that the pathogenesis of CAA‐ri may be mediated by a selective autoimmune reaction against cerebrovascular Aβ, directly related to autoantibody concentration and soluble Aβ. The CSF dosage of anti‐Aβ autoantibodies with the technique here described can thus be proposed as a valid alternative tool for the diagnosis of CAA‐ri. Moreover, given the similarities between ARIA developing spontaneously and those observed during immunization trials, anti‐Aβ autoantibodies can be considered as novel potential biomarkers in future amyloid‐modifying therapies for the treatment of AD and CAA. Ann Neurol 2013;73:449–458
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Another common pathogenetic aspect shared by ARIA and CAA-ri is the clearance of Ab protein from the CNS of immunized AD patients, indicating a massive drainage of Ab from the brain and vascular deposits to the soluble form during the first phases of treatment, before plaque removal.(2,33) This is in agreement with wh…”
ResultClinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015
Self-citationSperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 3×
“Dosage of anti-Ab antibodies with the technique described here can thus be suggested as a putative biomarker to monitor the abnormal events rising during the ongoing clinical trials of passive immunization.(1,2) On the basis of these considerations, we speculate that future applications of this technique might include…”
BackgroundResultSelf-citationA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · cited 6×
“Another common pathogenetic aspect shared by ARIA and CAA-ri is the clearance of Ab protein from the CNS of immunized AD patients, indicating a massive drainage of Ab from the brain and vascular deposits to the soluble form during the first phases of treatment, before plaque removal.(2,33) This is in agreement with wh…”
BackgroundResultInfluentialMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 1×
“Similar alterations have also been reported following treatment with other anti-amyloid drugs, such as avagacestat(3) and gantenerumab.(4) Currently, the pathogenetic mechanism of ARIA is still unknown, but among the most interesting hypotheses linking anti–amyloid b (Ab) antibody administration and VE is an abnormal…”
Clinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417 · cited 2×
“Discussion The pathogenesis of CAA-ri is still unknown, although the mechanism leading to the inflammatory process appears to be secondary to an autoimmune reaction against the Ab protein in the central nervous system (CNS).(7,8) Sporadic observations, such as a specific CD4(1) T-lymphocyte recruitment at the Ab depos…”
BackgroundSelf-citationScolding, N. J. (2005) · Brain · doi:10.1093/brain/awh379 · Cited by 372
Course of cerebral amyloid angiopathy–related inflammation
Kinnecom, C., Lev, M. H., Wendell, L., Smith, E. E., Rosand, J., Frosch, M. P., & Greenberg, S. M. (2007) · Neurology · doi:10.1212/01.wnl.0000260066.98681.2e · Cited by 333 · cited 1×
“CAA-ri is characterized by acute/subacute neurological impairment, headache, behavioral changes, seizures, and focal neurological deficits.(7,9) The MRI scans show signs of previous lobar hemorrhage and multiple areas of sulcal superficial siderosis and cortical/subcortical microbleeds demonstrated by T2*-GRE or susce…”
BackgroundSelf-citationZetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234 · cited 1×
“At the same time, the markers of axonal degeneration were increased in apCAA-ri and returned to control levels in rpCAA-ri, showing a downstream trend similar to that recently reported in AD patients treated with bapineuzumab.(34) To our knowledge, this is the first evidence that antiAb autoantibodies are directly inv…”
Result
Cited by
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Self-citationSöderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., Möller, C., & Lannfelt, L. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01308-6 · Cited by 427
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
Cerebral Amyloid Angiopathy: Emerging Concepts
Yamada, M. (2015) · Journal of Stroke · doi:10.5853/jos.2015.17.1.17 · Cited by 367
“Vasogenic edema was noted in 2 of 2,762 patients with AD at the baseline of the clinical trial; findings were compatible with CAA-related inflammation.114 As discussed above, CAA-related inflammation is associated with the presence of anti-Aβ autoantibodies in CSF.64,65 Further studies are required to elucidate the li…”
BackgroundInfluentialAuriel, E., Charidimou, A., Gurol, M. E., Ni, J., Van Etten, E. S., Martinez-Ramirez, S., Boulouis, G., Piazza, F., DiFrancesco, J. C., Frosch, M. P., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4078 · Cited by 359
Self-citationB cells in autoimmune and neurodegenerative central nervous system diseases
Sabatino, J. J., Pröbstel, A.-K., & Zamvil, S. S. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0233-2 · Cited by 343
Casson, A. J. (2019) · Biomedical Engineering Letters · doi:10.1007/s13534-018-00093-6 · Cited by 340
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery
Liu, Y.-H., Wang, Y.-R., Xiang, Y., Zhou, H.-D., Giunta, B., Mañucat-Tan, N. B., Tan, J., Zhou, X.-F., & Wang, Y.-J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8694-9 · Cited by 99
Blood–brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy
Kozberg, M. G., Yi, I., Freeze, W. M., Auger, C. A., Scherlek, A. A., Greenberg, S. M., & van Veluw, S. J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac245 · Cited by 94
Self-citationJianming, W., & Ling, L. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150131 · Cited by 87
Söllvander, S., Ekholm-Pettersson, F., Brundin, R.-M., Westman, G., Kilander, L., Paulie, S., Lannfelt, L., & Sehlin, D. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150236 · Cited by 60
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Qu, B.-X., Gong, Y., Moore, C., Fu, M., German, D. C., Chang, L.-Y., Rosenberg, R., & Diaz-Arrastia, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.017 · Cited by 47
The role of neuroinflammation in cerebral amyloid angiopathy
van den Brink, H., Voigt, S., Kozberg, M., & van Etten, E. S. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105466 · Cited by 39
Jeong, S. Y., Suh, C. H., Kim, S. J., Lemere, C. A., Lim, J.-S., & Lee, J.-H. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0105 · Cited by 26
“In the acute or subacute stage of CAA-ri, anti-A β autoantibodies in CSF are elevated and return to the typically observed level in patients with AD and noninflammatory CAA after clinicopathologic resolution [21,22].”
BackgroundMethod
Metadata
- Authors
- Piazza, F., Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. R., Giaccone, G., Tagliavini, F., Ferrarese, C., & DiFrancesco, J. C.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2013-04
- Volume
- 73
- Issue
- 4
- Pages
- 449-458
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1905168637
- Cited by
- 236
- References
- 12
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.